Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

Overview of attention for article published in British Journal of Haematology, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 11,026)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 86 news outlets
policy: 2 policy sources

twitter: 2 X users
patent: 1 patent

Readers on

mendeley: 71 Mendeley

So far, Altmetric has seen 162 news stories from 86 outlets.

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

Morning Star, 27 Feb 2024

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or…

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

Crwe World, 27 Feb 2024

- A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in…

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY(TM)) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Stockwatch, 27 Feb 2024

Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in…

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY(TM)) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

Stockwatch, 27 Feb 2024

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 158 additional news stories.